Ravi K Goyal
Overview
Explore the profile of Ravi K Goyal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brufsky A, Kwan M, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva A, et al.
Breast Cancer Res Treat
. 2024 Aug;
208(2):223-235.
PMID: 39177933
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) in clinical trials and real-world studies. However,...
2.
Diez-Campelo M, Yucel A, Goyal R, Parikh R, Esterberg E, Jimenez M, et al.
Future Oncol
. 2024 Aug;
20(27):1993-2004.
PMID: 39140298
To assess treatment patterns and outcomes in patients with non-del(5q) lower-risk myelodysplastic syndromes. Patient medical records were reviewed in the USA, Canada (CAN), UK and the EU. Analysis included 119...
3.
Mody F, Goyal R, Ajmera M, Davis K, Amin A
Drugs Real World Outcomes
. 2024 Aug;
11(3):501-511.
PMID: 39088143
Background: In patients with heart failure with reduced ejection fraction (HFrEF), lower discharge heart rate (HR) is known to be associated with better outcomes. However, the effect of HR control...
4.
Goyal R, Candrilli S, Abughosh S, Chen H, Holmes H, Johnson M
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927874
In hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC), cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) have replaced endocrine therapy alone as the standard of care; however, several...
5.
Furqan M, Karanth S, Goyal R, Cai B, Rombi J, Davis K, et al.
Future Oncol
. 2024 Apr;
20(22):1553-1563.
PMID: 38629593
To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14). In an oncologists-led retrospective review of medical records, data were abstracted...
6.
Goyal R, Zhang J, Davis K, Sluga-OCallaghan M, Kaufman P
Breast Cancer Res Treat
. 2024 Feb;
205(1):201-210.
PMID: 38310616
Purpose: In 2010, the US Food and Drug Administration approved eribulin for the treatment of metastatic breast cancer (MBC). Since then, the treatment landscape has evolved with many new therapy...
7.
Goyal R, Zhang J, Davis K, Sluga-OCallaghan M, Kaufman P
Breast Cancer (Dove Med Press)
. 2023 Nov;
15:855-865.
PMID: 38020049
Introduction: Eribulin was approved by the FDA in 2010 for the treatment of metastatic breast cancer (MBC) in the United States (US). More recently, several immuno-oncology (IO) and antibody-drug conjugate...
8.
Goyal R, Chen H, Abughosh S, Holmes H, Candrilli S, Johnson M
Cancer
. 2023 Feb;
129(7):1051-1063.
PMID: 36760031
Background: Evidence on overall survival (OS) with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors is generally limited to data from clinical trials or a few observational studies with limited generalizability...
9.
Paik P, Goyal R, Cai B, Price M, Davis K, Ansquer V, et al.
Future Oncol
. 2023 Feb;
19(3):217-228.
PMID: 36749292
To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in...
10.
Goyal R, Holmes H, Chen H, Abughosh S, Candrilli S, Johnson M
Breast Cancer Res Treat
. 2023 Jan;
198(1):159-166.
PMID: 36609900
Purpose: Delaying chemotherapy remains a vital goal in therapeutic management of HR+/HER2- metastatic breast cancer (MBC). However, recent reports continue to highlight substantially high chemotherapy utilization in earlier therapy lines....